Ethotoin

CHEMBL1095 Phase 4 Aprovado Small molecule

Half-Life

—

Bioavailability

—

Protein Binding

—

Molecular Weight

204.2 g/mol

LogP

1.0

Phase

4

This hydantoin anticonvulsant stabilizes nerve cell membranes to reduce the spread of abnormal electrical activity that causes seizures. It is used to treat certain types of epilepsy when other medications are not suitable.

Peso Molecular

204,2200 g/mol

LogP

1,00

TPSA

49,40 Å²

Regra dos 5 de Lipinski

Aprovado

Mecanismo de Ação

Modulates neuronal excitability through one or more mechanisms including blockade of voltage-gated sodium channels, enhancement of GABAergic inhibition, or modulation of calcium channels. This reduces the frequency and severity of seizure activity.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Mecanismo

Modulates neuronal excitability through one or more mechanisms including blockade of voltage-gated sodium channels, enhancement of GABAergic inhibition, or modulation of calcium channels. This reduces the frequency and severity of …

Estrutura 2D

SVG PNG

Cite this structure

Embed this structure

SMILES

CCN1C(=O)NC(c2ccccc2)C1=O

InChI

InChI=1S/C11H12N2O2/c1-2-13-10(14)9(12-11(13)15)8-6-4-3-5-7-8/h3-7,9H,2H2,1H3,(H,12,15)

Molecular Formula

C11H12N2O2

HBD / HBA

1 / 2

Ligações Rotacionáveis

2

Átomos Pesados

15

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Perguntas frequentes

This hydantoin anticonvulsant stabilizes nerve cell membranes to reduce the spread of abnormal electrical activity that causes seizures. It is used to treat certain types of epilepsy when other medications are not suitable.

Modulates neuronal excitability through one or more mechanisms including blockade of voltage-gated sodium channels, enhancement of GABAergic inhibition, or modulation of calcium channels. This reduces the frequency and severity of seizure activity.

Yes, Ethotoin is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1095. Open-access bioactivity database.
PubChem — National Center for Biotechnology Information (NCBI). CID 3292. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.

PillFYI

Procura informações acessíveis para o paciente?

Ethotoin no PillFYI

Estrutura

Dados Rápidos

Fórmula: C11H12N2O2

Links Externos

Cite

BibTeX, APA, MLA, Chicago, IEEE, Harvard

Aviso Médico

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.